Indeed, GNE-477 was significantly more potent than other PI3K-Akt-mTOR inhibitors (LY294002, AZD2014, perifosine) in inhibiting RCC cell survival and inducing cell apoptosis. The gene discussed is MTOR; the disease is renal cell carcinoma.